Physician profile
Guillermo E Calderon
NPI 1669478939
$1,720.11
in general payments reported to CMS, 2019-2025
27 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.23 · 2020: $123 · 2021: $189 · 2022: $297 · 2023: $375 · 2024: $310 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $457.46 | 2022-2025 | Veozah |
| Abbvie INC. | $300.34 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Gynesonics, INC. | $108.68 | 2021-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $108.27 | 2023-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Pfizer INC. | $106.02 | 2021-2024 | |
| Daiichi Sankyo INC. | $73.72 | 2019-2023 | Injectafer |
| Coopersurgical, INC. | $63.39 | 2020-2025 | Paragard T 380a |
| Monaghan Medical Corporation | $46.18 | 2024 | Aerochamber |
| Bayer Healthcare Pharmaceuticals INC. | $43.03 | 2023-2025 | |
| Avion Pharmaceuticals | $40.89 | 2022-2023 | Balcoltra |
| Cepheid | $38.61 | 2025 | |
| Medtronic, INC. | $34.47 | 2025 | Truclear |
| Northgate Technologies, INC. | $33.61 | 2024 | Stimsite |
| Intuitive Surgical, INC. | $33.18 | 2022 | |
| Boston Scientific Corporation | $31.56 | 2025 | Axonics |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $27.34 | 2020 | |
| Merck Sharp & Dohme LLC | $24.59 | 2025 | Bridion |
| Sumitomo Pharma America, INC. | $20.30 | 2023 | Myfembree |
| Channel Medsystems, INC. | $18.54 | 2023 | |
| Lupin INC. | $17.70 | 2021 | |
| Meditrina | $17.68 | 2025 | |
| Agile Therapeutics, INC. | $17.64 | 2024 | Twirla |
| Organon LLC | $15.31 | 2025 | Nexplanon |
| Minerva Surgical, INC | $14.94 | 2024 | |
| Therapeuticsmd, INC. | $13.75 | 2022 | |
| Kci USA, INC. | $12.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.